COMMUNIQUÉS West-GlobeNewswire

KFSHRC Performs World’s First Robotic Intracranial Tumor Resection ... A New Era in Neurosurgery
20/10/2025
RIYADH, Saudi Arabia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- In a historic leap for robotic medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world’s first [...]
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
20/10/2025
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit with more mature [...]
KFSHRC Performs World’s First Robotic Intracranial Tumor Resection ... A New Era in Neurosurgery
20/10/2025
RIYADH, Saudi Arabia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- In a historic leap for robotic medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world’s first [...]
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES
20/10/2025
Taipei, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
Solana Company Executive Chairman’s Message: October 20th, 2025
20/10/2025
NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ: HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong [...]
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
20/10/2025
LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming [...]
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
20/10/2025
Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc [...]
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
20/10/2025
Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 study investigators [...]
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
20/10/2025
Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical Director Immediate expansion is planned in [...]
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
20/10/2025
Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft tissue sarcoma (p<0.001) High level of tumour hyalinization/fibrosis, [...]
R1 Announces Strategic Partnership with Sierra to Revolutionize AI-Driven Experiences in Healthcare
20/10/2025
MURRAY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced a strategic partnership with Sierra, the leading AI-powered customer experience [...]
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
20/10/2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
20/10/2025
Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC’s Biotech Footprint in Asia KUALA LUMPUR, Malaysia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, “BGLC”, or the “ [...]
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
20/10/2025
Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
Arnatar Therapeutics Announces Upcoming Presentations at AASLD The Liver Meeting® 2025 and ASN Kidney Week 2025
20/10/2025
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, today announced that new preclinical data from its ACT-UP1 [...]
CervoMed to Present at the Emerging Growth Conference
20/10/2025
BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that [...]
Adaptyx Raises $14M in Seed Financing to Launch Wearable Platform for Continuous Multi-Analyte Molecular Monitoring
20/10/2025
MENLO PARK, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Adaptyx Biosciences , a biowearables company developing the first platform for continuous, multi-analyte molecular monitoring, today announced it has raised $14 [...]
Connect Expands Access to Funding Through Curated Venture List
20/10/2025
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Connect , a premier nonprofit organization in San Diego’s innovation ecosystem dedicated to supporting entrepreneurs and cultivating thriving life science and technology [...]
Valitor Presents Preclinical Data Demonstrating VLTR-559 Achieves Superior Durability and Sustained Anti-VEGF Activity with a Favorable Safety Profile as a Treatment for Wet AMD
20/10/2025
Preclinical results support 6-month dosing, demonstrating VLTR-559’s substantially longer ocular half-life, with high drug concentrations retained in the retina compared to current anti-VEGF standard of care VLTR-559 [...]

Pages